Edition:
India

Perrigo Company PLC (PRGO.N)

PRGO.N on New York Stock Exchange

89.55USD
16 Feb 2018
Change (% chg)

$-0.10 (-0.11%)
Prev Close
$89.65
Open
$89.27
Day's High
$90.72
Day's Low
$89.26
Volume
280,901
Avg. Vol
302,072
52-wk High
$95.82
52-wk Low
$63.69

Latest Key Developments (Source: Significant Developments)

Perrigo Announces Final FDA Approval And Launch Of An AB Rated Generic Version Of Epiduo Gel
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - Perrigo Company Plc ::PERRIGO ANNOUNCES FINAL FDA APPROVAL AND LAUNCH OF AN AB RATED GENERIC VERSION OF EPIDUO GEL.  Full Article

Perrigo Says In Connection With Uwe Röhrhoff's Appointment As CEO, Co's Unit Perrigo DAC Entered Into Employment Agreement With Him
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Perrigo Company Plc ::PERRIGO COMPANY - IN CONNECTION WITH UWE RÖHRHOFF'S APPOINTMENT AS CEO, CO'S UNIT PERRIGO DAC ENTERED INTO AN EMPLOYMENT AGREEMENT WITH HIM.PERRIGO COMPANY PLC - PERRIGO DAC EMPLOYMENT AGREEMENT HAS AN INITIAL TERM OF THREE YEARS.PERRIGO COMPANY PLC - PERRIGO DAC EMPLOYMENT AGREEMENT PROVIDES THAT RÖHRHOFF WILL BE ENTITLED TO AN ANNUAL BASE SALARY OF EUR 850,000.PERRIGO COMPANY PLC - RÖHRHOFF WILL ALSO RECEIVE A EUR 850,000 SIGN-ON BONUS, TO BE PAID EUR 425,000 IN CASH AND EUR 425,000 IN RSUS.PERRIGO SAYS RÖHRHOFF TO BE ENTITLED TO TARGET ANNUAL BONUS OPPORTUNITY OF NO LESS THAN 125% OF ANNUAL BASE SALARY- SEC FILING.  Full Article

Perrigo appoints Uwe Röhrhoff as CEO
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Perrigo Company Plc ::PERRIGO APPOINTS UWE RÖHRHOFF AS PRESIDENT & CHIEF EXECUTIVE OFFICER.PERRIGO COMPANY- ‍ANNOUNCED APPOINTMENT OF UWE RÖHRHOFF AS CHIEF EXECUTIVE OFFICER, EFFECTIVE JANUARY 15, 2018, FOLLOWING RETIREMENT OF JOHN T. HENDRICKSON​.‍JOHN T. HENDRICKSON TO REMAIN WITH COMPANY UNTIL MARCH 15, 2018 TO ENSURE SUCCESSFUL TRANSITION​.  Full Article

Perrigo Announces Tentative FDA Approval For The Generic Version Of Prolensa Ophthalmic Solution 0.07%
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Perrigo Company Plc ::PERRIGO ANNOUNCES TENTATIVE FDA APPROVAL FOR THE GENERIC VERSION OF PROLENSA® OPHTHALMIC SOLUTION 0.07%.  Full Article

Perrigo Company ‍Launch AB Rated Generic Version Of Exalgo 32mg
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Perrigo Company Plc ::PERRIGO COMPANY PLC - ‍LAUNCH OF AN AB RATED GENERIC VERSION OF EXALGO 32MG EXTENDED RELEASE TABLETS C-II​.  Full Article

Perrigo Company completes divestiture of API business for $110 million
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Perrigo Company PLC :Perrigo Company completes divestiture of API business for $110 million.  Full Article

Perrigo Q3 GAAP EPS $0.31
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Perrigo Company PLC :Perrigo Company PLC reports third quarter 2017 financial results.Q3 sales $1.2 billion versus I/B/E/S view $1.17 billion.Sees FY 2017 adjusted earnings per share $4.80 to $4.95.Sees FY 2017 earnings per share $0.74 to $0.89.Q3 adjusted earnings per share $1.39 excluding items.Q3 gaap earnings per share $0.31.Q3 earnings per share view $1.11 -- Thomson Reuters I/B/E/S.  Full Article

Perrigo announces tentative FDA approval for a first-to-file generic version of Picato Gel 0.05 pct
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Perrigo Company Plc :Perrigo announces tentative fda approval for a first-to-file generic version of Picato Gel 0.05 pct.‍Received tentative approval from FDA for generic version of Picato Gel 0.05 pct​.  Full Article

Perrigo announces patent litigation settlement for generic version of Onexton® Gel
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Perrigo Company Plc :Perrigo announces patent litigation settlement for the generic version of Onexton® Gel.Perrigo Company Plc - ‍details of settlement are confidential​.Perrigo Company Plc - ‍settled Hatch-Waxman litigation relating to Onexton Gel ​.Perrigo Company - settled ‍litigation relating to Onexton Gel brought by Valeant Pharmaceuticals North America LLC and Dow Pharmaceutical Sciences​.  Full Article

Perrigo announces tentative FDA approval for generic version of Picato gel.015%
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Perrigo Company Plc :Perrigo announces tentative FDA approval for a first-to-file generic version of Picato Gel .015%.‍RPT-Perrigo announces tentative FDA approval for a first-to-file generic version of Picato Gel .015%​.  Full Article

BRIEF-Perrigo Announces Tentative FDA Approval For The Generic Version Of Soolantra Cream, 1%

* PERRIGO ANNOUNCES TENTATIVE FDA APPROVAL FOR THE GENERIC VERSION OF SOOLANTRA® CREAM, 1% Source text for Eikon: Further company coverage: